Dicerna pharmaceuticals, inc. (DRNA)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
CASH FLOWS FROM OPERATING ACTIVITIES:
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss

-120,459

-88,853

-60,200

-59,513

-62,839

-47,939

-18,518

-10,121

Adjustments to reconcile net loss to net cash provided by operating activities:
Non-cash litigation expense

0

10,315

0

0

-

-

-

-

Stock-based compensation expense

18,822

7,888

7,770

9,165

9,732

8,237

495

125

Depreciation and amortization expense

1,254

800

800

800

727

848

740

776

Loss on disposal of property and equipment

-

-

-

0

-

-

-

-

Amortization of premium on investments

3,559

1,126

169

-73

134

-

-

-

Non-cash lease expense

2,747

-

-

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-

-143

-318

-

Increase in fair value of preferred stock warrant

-

-

-

-

-

2,559

-126

-469

Changes in operating assets and liabilities:
Litigation settlement payable

-10,500

10,500

0

0

-

-

-

-

Deferred revenue

211,803

173,916

9,270

0

-

-

-

1,014

Research and license receivable

-

-

-

-

-

-

-5,018

4,857

Prepaid expenses and other assets

3,856

-532

1,459

414

177

1,171

-57

-28

Accounts payable

2,067

-1,217

626

1,644

1,384

-97

116

-216

Contract receivables

100,354

100,000

0

0

-

-

-

-

Withholding tax receivable

0

-1,583

1,583

0

-

-

-

-

Accrued expenses and other liabilities

9,487

3,974

-411

-542

2,240

2,656

1,016

49

Lease liability

8,966

-

-

-

-

-

-

-

Other

-191

12

51

-

-

-

-

-

Other

-1,013

0

0

-

-

-

-

-

Deferred rent

-

-

-

-

-

-

60

38

Net cash provided by operating activities

-692

18,298

-45,327

-48,747

-48,799

-34,764

-10,944

-15,737

CASH FLOWS FROM INVESTING ACTIVITIES:
Change in restricted cash equivalents

-

-

-

-

-264

1,116

-

-

Maturities of held-to-maturity investments

418,000

81,000

70,000

48,500

70,000

9,995

-

-

Purchases of held-to-maturity investments

362,120

283,372

89,719

35,031

36,129

82,627

-

-

Purchases of property and equipment

6,349

359

133

449

1,134

2,013

413

120

Proceeds from public offering of common stock, net of transaction costs (Note 8)

-

-

-

-

45,438

94,148

-

-

Repurchase of restricted common stock

-

-

-

-

-

-

5

-

Net cash (used in) provided by investing activities

49,531

-202,731

-19,852

13,020

33,001

-75,761

-413

-120

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock, net of placement agent commissions

0

108,099

43,225

0

-

-

-

7

Payments of common stock offering costs

50

703

23

0

-

-

1,399

-

Proceeds from issuance of redeemable convertible preferred stock

0

0

70,000

0

-

-

57,000

-

Redeemable convertible preferred stock issuance costs

0

0

750

0

-

-

220

-

Proceeds from issuance of common stock to collaboration partners

45,828

60,412

0

0

-

-

-

-

Proceeds from exercises of stock options and issuances under Employee Stock Purchase Plan

7,110

2,110

290

561

427

875

46

-

Proceeds from bridge loan financing

-

-

-

-

-

-

3,000

-

Payments of long-term debt fees

-

-

-

-

-

-

-

136

Settlement of restricted stock for tax withholding

0

35

11

27

76

-

-

-

Repayments of long-term debt

-

-

-

-

-

5,026

4,140

2,834

Net cash provided by financing activities

52,888

169,883

112,731

534

45,789

89,997

54,282

-2,963

NET INCREASE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH EQUIVALENTS

101,727

-14,550

47,552

-35,193

29,991

-20,528

42,925

-18,820

SUPPLEMENTAL CASH FLOW INFORMATION:
Accretion of redeemable convertible preferred stock

-

-

-

-

-

204

2,388

4,097

Deemed contribution of preferred stockholders

-

-

-

-

-

-

16,170

-

Conversion of bridge loan financing

-

-

-

-

-

-

3,000

-

NONCASH OPERATING ACTIVITIES
Right-of-use assets acquired through operating leases

25,725

-

-

-

-

-

-

-

NONCASH INVESTING ACTIVITIES
Property and equipment purchases included in accounts payable and accrued expenses

727

1,648

15

53

112

-

-

-

NONCASH FINANCING ACTIVITIES
Convertible Temporary Equity Share Issued Upon Conversion Value

0

0

79,361

0

-

-

-

-

Dividends on redeemable convertible preferred stock

0

0

10,111

0

-

-

-

-

Deemed dividend related to beneficial conversion feature of redeemable convertible preferred stock

0

0

6,144

0

-

-

-

-

Deemed dividend on conversion of redeemable convertible preferred stock

0

0

3,837

0

-

-

-

-

Common stock offering costs included in accounts payable or accrued expenses

0

50

423

0

-

-

-

-

Right-of-use assets acquired through financing leases

193

-

-

-

-

-

-

-

Warrant conversion to common stock

-

-

-

-

-

3,088

-

-

Cash paid for interest

-

-

-

-

-

194

771

1,123